Erleada (Apalutamide) First Drug Approved by the FDA for ... | 合法藥品大搜索

由LFala著作·被引用1次—OnFebruary14,2018,apalutamide(Erleada;Janssen)wasapprovedbytheUSFoodandDrugAdministration(FDA)forthetreatmentofpatientswith ...

Prostate cancer, the second most common type of cancer in men, is expected to affect 11.6% of all men during their lifetime.1 In fact, more than 3 million men in the United States are living with prostate cancer. It is estimated that in 2017, 161,360 men were newly diagnosed with prostate cancer, and 26,730 men died from the disease.1

Approximately 10% to 20% of patients with prostate cancer have castration-resistant disease, an aggressive form that often continues to progress despite hormone therapy, and approximately 16% of these patients have nonmetastatic prostate cancer at the time of their diagnosis.2,3 Among patients diagnosed with nonmetastatic castration-resistant prostate cancer (CRPC), approximately 33% will have progressive disease that will become metastatic cancer within 2 years.3

Prostate cancer most often metastasizes to the bones, lymph nodes, adrenal gland, lung, and liver.4 Metastatic prostate cancer is associated with an increased rate of compli...